Barbara Hildesheim-Nuesslein
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications
Lost in translation: rethinking animal models of progressive MS (an industry perspective).
Journal: Multiple sclerosis and related disorders
Published: May 30, 2025
Lymphotoxin-dependent elevated meningeal CXCL13:BAFF ratios drive gray matter injury.
Journal: Nature immunology
Published: January 07, 2025
Remibrutinib (LOU064) inhibits neuroinflammation driven by B cells and myeloid cells in preclinical models of multiple sclerosis.
Journal: Journal of neuroinflammation
Published: February 03, 2023
Preclinical characterization of the Toll-like receptor 7/8 antagonist MHV370 for lupus therapy.
Journal: Cell reports. Medicine
Published: September 21, 2022
Discovery of LOU064 (Remibrutinib), a Potent and Highly Selective Covalent Inhibitor of Bruton's Tyrosine Kinase.
Journal: Journal of medicinal chemistry
Published: February 22, 2020
FTY720 reactivates cryptococcal granulomas in mice through S1P receptor 3 on macrophages.
Journal: The Journal of clinical investigation
Published: December 30, 2019
Siponimod therapy implicates Th17 cells in a preclinical model of subpial cortical injury.
Journal: JCI insight
Published: August 09, 2019
Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: September 03, 2014
Discovery of BAF312 (Siponimod), a Potent and Selective S1P Receptor Modulator.
Journal: ACS medicinal chemistry letters
Published: November 15, 2012
A sphingosine-1-phosphate receptor 1-directed agonist reduces central nervous system inflammation in a plasmacytoid dendritic cell-dependent manner.
Journal: Journal of immunology (Baltimore, Md. : 1950)
Published: August 31, 2012
Last Updated: 09/26/2026